Swedish Orphan Biovitrum’s NASP Journey: FDA Feedback and Market Outlook

The FDA’s recent Complete Response Letter (CRL) for Swedish Orphan Biovitrum AB’s (SOBI) biologics license application (BLA) for NASP—a nanoencapsulated sirolimus plus pegadricase combination—marks a pivotal moment in the company’s effort to bring a novel therapy for uncontrolled gout to the U.S. market. The CRL, issued on 26 June 2026, reflects the agency’s request for additional data on chemistry, manufacturing, and controls (CMC) as well as contract manufacturing facilities, while affirming that no clinical safety or efficacy concerns have been identified.

FDA’s Key Requests

  • Chemistry, Manufacturing, and Controls (CMC): The agency requires expanded documentation on the control strategy for NASP’s biologic component, focusing on stability, purity, and process validation.
  • Contract Manufacturing Facilities: The FDA identified deficiencies at a contract manufacturer, necessitating remediation before resubmission can proceed.
  • Clinical Profile: Importantly, the letter confirms that the clinical data set demonstrates acceptable safety and efficacy, a positive signal that the product’s therapeutic benefit profile remains intact.

SOBI has already scheduled a meeting with FDA officials to discuss the feedback and to delineate a clear resubmission pathway. The company’s emphasis on addressing the CMC and manufacturing gaps underscores a commitment to meeting regulatory expectations while preserving the integrity of its clinical evidence.

Market Reaction and Analyst Sentiment

Following the CRL announcement, Danske Bank elevated its target price for SOBI to 462 SEK from 435 SEK, maintaining a “hold” recommendation. The brokerage’s upward revision reflects confidence that the company’s robust pipeline and strong balance sheet will support a successful resubmission. With a market cap of 159 billion SEK and a trading range that has recently hovered around 466 SEK (close on 25 June 2026), investors are keenly watching how SOBI navigates the FDA’s requirements.

Forward‑Looking Perspective

SOBI’s history of developing therapies for rare and debilitating diseases—ranging from haemophilia to genetic conditions—positions it well to absorb the temporary setback posed by the CRL. The company’s global footprint and established manufacturing network provide a foundation for rapid remediation of the identified deficiencies. Moreover, the absence of clinical concerns in the FDA’s letter suggests that the therapeutic potential of NASP remains compelling, and a well‑executed resubmission could restore confidence in the U.S. market.

From an insider viewpoint, the next few months will be decisive. A successful resolution of the CMC and manufacturing issues could catalyse a renewed surge in investor sentiment, particularly if the company can demonstrate a clear timeline for resubmission and eventual approval. The market’s willingness to lift its target price indicates that, beyond the immediate regulatory hurdles, there is strong belief in SOBI’s long‑term strategic trajectory.